Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Lakshini Y Herat, Vance B Matthews, Aaron L Magno, Marcio G Kiuchi, Revathy Carnagarin & Markus P Schlaich. (2020) An evaluation of empagliflozin and it’s applicability to hypertension as a therapeutic option. Expert Opinion on Pharmacotherapy 21:10, pages 1157-1166.
Read now
Read now
André J. Scheen. (2017) Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:5, pages 583-592.
Read now
Read now
André J. Scheen. (2016) DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opinion on Drug Metabolism & Toxicology 12:12, pages 1407-1417.
Read now
Read now
Articles from other publishers (7)
Anil Kumar Goud Thallapalli & Ram Mohan Manda. (2023) Development and validation of Empagliflozin and Linagliptin simultaneous estimation in rat plasma using freezing lipid precipitation and SCX-SPE assisted HPLC–MS/MS method and its application in pharmacokinetic studies. Analytical Sciences.
Crossref
Crossref
Santenna Chenchula, Shoban Babu Varthya & R. Padmavathi. (2022) Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies. Current Diabetes Reviews 18:4.
Crossref
Crossref
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
1
41
.
Priyanka A. Shah, Pranav S. Shrivastav & Archana George. (2019) Mixed-mode solid phase extraction combined with LC-MS/MS for determination of empagliflozin and linagliptin in human plasma. Microchemical Journal 145, pages 523-531.
Crossref
Crossref
Annayya R. Aroor, Camila Manrique-Acevedo & Vincent G. DeMarco. (2018) The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. Cardiovascular Diabetology 17:1.
Crossref
Crossref
André J. Scheen. (2016) Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. Clinical Pharmacokinetics 56:7, pages 703-718.
Crossref
Crossref
Kyu Chan Kwon & Chulung Lee. (2017) Analysis of Fixed-Dose Combination Products Approved by the US Food and Drug Administration, 2010–2015: Implications for Designing a Regulatory Shortcut to New Drug Application. Therapeutic Innovation & Regulatory Science 51:1, pages 111-117.
Crossref
Crossref